Yes, I will most certainly do searches on both Medline and Cinahl.
Infection and thrombosis risk should be included. Extravasation will happen also from central lines, true. Although much less frequent, right?
I was just wondering if you, or anyone else, could direct me to literature/evidence on such things as early assessment, haemodilution, vein damage from peripherals, comparative extravasation risk central/peripheral administration etc. Maybe you know of articles that really must be included.
The text is for a medical national guideline for breast cancer treatment and my part will be 1/2 page or more if I can motivate that. So it’s mostly for physicians and to some extent for nurses.
Thanks
Mats
Den 05-12-23 00.36, skrev "Lynn Hadaway" <[EMAIL PROTECTED]>:
There is a ton of articles you could include. I would do a literature search using PubMed found at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
Also, I would be very careful about the extravasation issue as this can and does occur with all central lines. It can be caused by a complete fibrin sheath or by a dislodged implanted port needle or by a fractured catheter from pinch-off syndrome.
Definitely emphasize the need for a brisk blood return before each and every dose of medication, especially vesicant chemo. You also must include the infection risk with a CVC. So I am not so sure you can get all this into a half page. Is this for patient or staff education? Lynn
At 7:31 PM +0100 12/22/05, Mats Strömberg wrote:
Dear listers,
I am going to write about half a page on vascular access device choice for
breast cancer patients. It is part of a larger set of guidelines for breast
cancer.
The things I would like to address are:
- The importance of early assessment
- The advantages of central venous access devices (like better hemodilution
preserving the veins, lower risk for extravasation)
- The individual advantages of implanted ports, PICCs and Hickman lines
- When to opt for peripheral access
Is this the things that I should address?
I need to show the evidence base for everything. What is the evidence for
these things? What is the important litterature to use as references?
Thanks in advance
Mats in Stockholm
----
Mats Strömberg, RN, Research nurse
Dept. of Oncology
Karolinska University Hospital, Solna
SE-171 76 Stockholm
E-mail: [EMAIL PROTECTED]
Phone int: +46 8 517 76376
Mobile phone int: +46 70 471 6661
--
Lynn Hadaway, M.Ed., RNC, CRNI
Lynn Hadaway Associates, Inc.
126 Main Street, PO Box 10
Milner, GA 30257
http://www.hadawayassociates.com
office 770-358-7861
